ArticleCardiovascular diagnosis and therapy2026
Apelin-13 attenuates doxorubicin-induced myocardial injury via the PI3K/AKT and ERK/MAPK signaling pathways.
Article in Cardiovascular diagnosis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anthracyclines play a crucial role in the chemotherapy of various malignant tumors; however, they may cause myocardial injury, which limits their clinical application. Therefore, it is of great importance to investigate drugs for the prevention and treatment of anthracycline-induced myocardial injury. The aim of this study is to evaluate the cardioprotective effects of Apelin-13 in a murine model of doxorubicin (DOX)-induced myocardial injury and to elucidate its potential underlying mechanisms. Methods: Male C57BL/6 mice (8 weeks old) were randomly assigned to four groups, with all mice received intraperitoneal injections: Control (normal saline), DOX (with a cumulative dose of 20 mg), Apelin-13 (Apelin-13 0.1 μmol/kg/d), and Apelin-13 + DOX (Apelin-13 0.1 μmol/kg/d; with a cumulative dose of 20 mg). Cardiac function was assessed using echocardiography. Histopathological changes were assessed via hematoxylin and eosin (HE) staining, and myocardial fibrosis was evaluated with Masson's trichrome staining. Immunohistochemical analysis and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining were conducted to assess protein expression and cardiomyocyte apoptosis, respectively. Protein expression levels were further validated by western blotting (WB). Results: In mice studies, no mice died during or after the drug intervention period. It was found that Apelin-13 could significantly increase left ventricular ejection fraction (LVEF) and fractional shortening (FS) (P<0.05) and decrease left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) (P<0.05) in mice with DOX-induced cardiomyopathy, as well as alleviate the disordered arrangement of myocardial cells and alleviate the reduction in cross-sectional area (CSA) induced by DOX. Masson staining and immunohistochemistry showed that Apelin-13 could alleviate myocardial fibrosis. WB indicated that Apelin-13 could reduce apoptosis induced by DOX and change the effects of DOX on the transforming growth factor-β (TGF-β)/mothers against decapentaplegic homolog (Smad) proteins. Further research confirmed that the protective effect of Apelin-13 on DOX-induced cardiomyopathy was related to the upregulation of P-ERK and P-AKT. Similarly, in H9C2 studies, it was found that Apelin-13 could reduce DOX-induced apoptosis, increase cell survival rate, and alleviate the decrease in P-ERK and P-AKT induced by DOX. Conclusions: Apelin-13 exerted a protective effect against DOX-induced myocardial injury in both C57BL/6 mice and H9C2 cardiomyocytes. This cardio protection was mediated, at least in part, through modulation of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) and extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.